Concert Sings 'All That Jazz' With D-SXB Licensing Deal
By Marie Powers
Staff Writer
Staff Writer
Privately held Concert Pharmaceuticals Inc. struck another business development high note, inking an exclusive license agreement that provides Jazz Pharmaceuticals plc with global rights to develop and commercialize deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323, aimed at narcolepsy.